Secondary screening

Focused screening

Fluofarma has developed a panel of assays for focused secondary screening in cell-based models of human diseases or in primary cell cultures. Our cell-based models enable reliable, targeted screening for a specific pathology.

Example of secondary screening in neurobiology

Fluofarma developed cellular models that mimic neurodegenerative disease. Those models are based on primary cultures of neurons grown in presence of neurodegeneration inducers.

As shown by the Figure below, focused screenings using those models allow the identification of drugs able to delay the neurodegeneration process (green).

 

Example of secondary screening in oncology

Fluofarma has a large panel of cancer cell lines which are representative of the major tumor types, as well as engineered cell lines overexpressing specific targets for more focused screening.

These cell-based tools enable allow the identification of drugs which act on a specific cancer type or a specific target.



Download Neurobiology.pdf
Download Oncology.pdf

Breaking news

  • Scientific Publication

    Fluofarma is glad to announce a new scientific publication in the journal Biochimica et Biophysica Acta - Molecular Cell Research.

    Read more [+]

  • IFSCC 2008

    Fluofarma will be attending IFSCC 2008, in Barcelona, from October 6th to 9th.

    Read more [+]

  • INVITOX 2008

    Fluofarma will be attending the INVITOX 2008 meeting, in Stockholm from September 25th to 28th.

    Read more [+]

  • EuroBio 2008

    Fluofarma will be attending EuroBio 2008, in Paris from October 7th to 9th.

    Read more [+]

  • SMi's Cell-Based Assays 2008

    Fluofarma will be attending SMi's Cell-Based Assays conference, in London from November 19th to 20th.

    Read more [+]

  • GDDI Forum 2009

    Fluofarma will be attending Global Discovery & Development Innovation Forum 2009, in London, from March 2nd to 3rd.

    Read more [+]

FOCUS: Anticancer drugs profiling
Fluofarma has developed DCffer® method, a powerful approach to compare and profile your anti-cancer drugs. Read more [+]